-
NCFBE Hospitalizations Costs Across Different Healthcare Systems: Insights From England and France in 2022 Using PMSI and HES Databases
Sep 9, 2025, 16:22 PM -
Innovative Drug Access in Portugal: An Analysis of Managed Entry Agreements Supporting Public Coverage 2014-2024
Sep 9, 2025, 16:22 PM -
Economics of Improved Time in Range in Type 1 Diabetes Management in Italy, Spain, Greece, and Israel
Sep 9, 2025, 16:22 PM -
Zoom Out: Simplifying Complex Health Economic Model Structure Through Artificial Intelligence
Sep 9, 2025, 16:22 PM -
Integrating Prospective and Retrospective Real-World Data to Construct External Comparator Arms: Novel Methods and Design Considerations
Sep 9, 2025, 16:22 PM -
Evaluating the Impact of International Drug Pricing Strategies on Indian State-Level
Sep 9, 2025, 16:22 PM -
Life-Cycle Stage-Specific Prioritization of Joint Clinical Assessment PICOs: Balancing Access Potential Feasibility and Likelihood
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Linzagolix 200 mg Plus Add-back Therapy (Linzagolix+ABT) for Symptomatic Treatment of Endometriosis
Sep 9, 2025, 16:22 PM -
The Elusive PICO: Assessing Prediction in Joint Clinical Assessments (JCA): A Case Study in Soft Tissue Sarcoma (STS)
Sep 9, 2025, 16:22 PM -
Digital Twins: Hype or Hope for Better Health Outcomes
Sep 9, 2025, 16:22 PM -
Methodological Acceptability of the Economic Analyses Assessed by the HAS in 2024
Sep 9, 2025, 16:22 PM -
Significant Burden of Chronic Obstructive Pulmonary Disease (COPD) on Health Status and Well-Being Persists Among Patients Experiencing One Severe or Two or More Moderate Exacerbations of COPD (ECOPD) and Their Caregivers (CGs)
Sep 9, 2025, 16:22 PM -
Mobility and Upper Extremity Function in Duchenne Muscular Dystrophy: A Longitudinal Survey Using PROMIS
Sep 9, 2025, 16:22 PM -
Quality of Systematic Reviews With Network Meta-Analyses on JAK Inhibitors in the Treatment of Rheumatoid Arthritis: Application of the AMSTAR 2 Scale
Sep 9, 2025, 16:22 PM -
Evolving Payer Preferences for Health Economic Information and Communication in the US
Sep 9, 2025, 16:22 PM -
Cost Utility of Subcutaneous Methotrexate As a Second-Line Treatment for Moderate to Severe Rheumatoid Arthritis in the UK
Sep 9, 2025, 16:22 PM -
Trends in EMA-Approved New Medicines 2015-2024: New Mechanisms of Action and Regulatory Shifts
Sep 9, 2025, 16:22 PM -
What Does the New ILAP Refresh Mean for Pharmaceutical Development and Patient Access in the UK?
Sep 9, 2025, 16:22 PM -
What Are the Likely PICOs for Tovorafenib and Lifileucel as the First Products to Go Through the JCA?
Sep 9, 2025, 16:22 PM -
The Estimation of the Prevalent Presymptomatic Type 1 Diabetes Population in Germany Using a Patient Funnel Model
Sep 9, 2025, 16:22 PM
